126 related articles for article (PubMed ID: 37796750)
1. Recurring Pancreatic Neuroendocrine Tumor: Timing and Pattern of Recurrence and Current Treatment.
Pulvirenti A; Javed AA; Michelakos T; Sekigami Y; Zheng J; Kalvin HL; McIntyre CA; Nebbia M; Chou JF; Gonen M; Raj N; Reidy-Lagunes DL; Zureikat AH; Ferrone CR; He J; Wei AC;
Ann Surg; 2023 Nov; 278(5):e1063-e1067. PubMed ID: 37796750
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
[TBL] [Abstract][Full Text] [Related]
3. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
4. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
7. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
8. The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
de Mestier L; Védie AL; Faron M; Cros J; Rebours V; Hentic O; Do Cao C; Bardet P; Lévy P; Sauvanet A; Ruszniewski P; Hammel P
Neuroendocrinology; 2020; 110(11-12):967-976. PubMed ID: 31791037
[TBL] [Abstract][Full Text] [Related]
9. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors.
Pulvirenti A; Javed AA; Landoni L; Jamieson NB; Chou JF; Miotto M; He J; Gonen M; Pea A; Tang LH; Nessi C; Cingarlini S; D'Angelica MI; Gill AJ; Kingham TP; Scarpa A; Weiss MJ; Balachandran VP; Samra JS; Cameron JL; Jarnagin WR; Salvia R; Wolfgang CL; Allen PJ; Bassiy C
Ann Surg; 2021 Dec; 274(6):1051-1057. PubMed ID: 31567347
[TBL] [Abstract][Full Text] [Related]
10. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
[TBL] [Abstract][Full Text] [Related]
12. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
[TBL] [Abstract][Full Text] [Related]
13. Early-Onset Pancreatic Neuroendocrine Tumors: Clinical Presentation, Pathology Features, and Oncological Outcomes.
Pulvirenti A; Hauser HF; Fiedler LM; McIntyre CA; Le T; Reidy-Lagunes DL; Soares KC; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Raj N; Wei AC
Ann Surg; 2024 Jan; 279(1):125-131. PubMed ID: 37325926
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors.
Rosenblum RE; Harris CK; Baeg KJ; Starr JA; Brais LK; Stashek KM; Ward SC; Katona BW; Clancy TE; Wisnivesky JP; Kulke MH; Metz DC; Kim MK; Chan JA
Pancreas; 2020 Feb; 49(2):249-254. PubMed ID: 32011530
[TBL] [Abstract][Full Text] [Related]
15. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
Wang WQ; Zhang WH; Gao HL; Huang D; Xu HX; Li S; Li TJ; Xu SS; Li H; Long J; Ye LY; Wu CT; Han X; Wang XH; Liu L; Yu XJ
J Gastroenterol; 2021 Apr; 56(4):395-405. PubMed ID: 33742253
[TBL] [Abstract][Full Text] [Related]
16. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
[TBL] [Abstract][Full Text] [Related]
17. Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group.
Lopez-Aguiar AG; Zaidi MY; Beal EW; Dillhoff M; Cannon JGD; Poultsides GA; Kanji ZS; Rocha FG; Marincola Smith P; Idrees K; Beems M; Cho CS; Fisher AV; Weber SM; Krasnick BA; Fields RC; Cardona K; Maithel SK
Ann Surg Oncol; 2019 Aug; 26(8):2517-2524. PubMed ID: 31004295
[TBL] [Abstract][Full Text] [Related]
18. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
19. Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreas; 2019 Aug; 48(7):943-947. PubMed ID: 31268980
[TBL] [Abstract][Full Text] [Related]
20. Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors.
Partelli S; Landoni L; Andreasi V; Nessi C; Muffatti F; Crippa S; Cingarlini S; Bassi C; Falconi M
Surgery; 2020 Nov; 168(5):816-824. PubMed ID: 32778411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
